The gene variants of the chemokine and chemokine receptor genes associated with inflammation may be involved in cancer initiation and progression. The aim of this study was to explore the possible association of monocyte chemoattractant protein-1 (MCP-1) A2518G and chemokine receptor CCR2A V64I gene polymorphisms with the risk and clinicopathological characteristics of bladder cancer (BC) in a Turkish population. In the present study, 142 individuals diagnosed with histologically confirmed BC between 2008-2011 at the Department of Urology, Istanbul Faculty of Medicine were enrolled as a patient group. The control group (n=197) consisted of urology patients who were treated at our outpatient clinic for various urological complaints but had no evidence of any malignancy based on a detailed evaluation. MCP-1 A2518G and CCR2A V64I gene polymorphisms were assessed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) in all subjects. For the statistical analyses Pearsons’s Chi-Squared (χ2) , Mann-Whitney U and multiple logistic regression model tests were used where appropriate. There were no significant differences in the distributions of MCP-1 A2518G genotypes between controls and BC patients. However, the carriers with AA genotype or at least one A allele of CCR2 had an increased risk of developing BC (aOR=2.39, 95%CI=1.13-5.03; p=0.022; aOR=1.37, 95%CI=1.04-1.81; p=0.022 respectively). In addition BC patients with AA genotype or at least one A allele of CCR2 had an increased risk of high grade and stage tumors as compared to those with GG genotype (aOR=3.09, 95%CI=1.02-9.34; p=0.045; aOR=1.58, 95%CI=1.07-2.32; p=0.020 respectively). On the other hand, MCP-1 A2518G gene polymorphism was not associated with the clinicopathological characteristics of BC. Our results suggest that the genetic variants of CCR2A V64I gene polymorphism may modify the BC risk. Furthermore, CCR2A V64I gene polymorphism may contribute to the muscle invasive BC in a Turkish population.